Sinovac Biotech

Since early March, Sinovac stock has made an increase of more than 400%!

In June, Sinovac received the first order in China to supply its pandemic influenza A (H1N1) vaccine to the Beijing government. The initial order consisted of vaccines for 2 million people; delivery is expected by the end of September with additional orders expected to commence in October.
In August, Sinovac announced it was the first company in the world to have completed H1N1 human vaccination trials.
It also announced mid-August that its profits jumped 76% year over year. Over the past five years, the sales growth has been more than 1500%!

According to the latest data, the World Health Organization estimates that nearly 2 billion people will be affected by Swine Flu in the next twelve months. China might need as many as half a billion swine flu shots in the next 6 months. This is excellent news for Sinovac.

I am a buyer of Sinovac (AMEX ticker: SVA) once price pulls back to a zone located between the 13 day and the 22 day moving averages.

--

What you can read on their website (www.sinovac.com):

Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. Sinovac is one of the leading emerging biotechnology companies in China. On August 18, Sinovac announced positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine.

The analysis of the clinical trial results showed that the H1N1 vaccine developed by Sinovac induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac’s H1N1 vaccine has good immunogenicity and offers protection.